CrushSCI.com
159.5平均天数
156中位天数
44最短天数
303最长天数
1682025发文量

Paper Review Records

全部论文审稿周期

21 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

158 天

Validation of the Ontario Protocol Assessment Level (OPAL) Tool for Assessing Clinical Trial Complexity and Supporting Workforce Planning in the Italian Clinical Research Context

作者
Daniele Napolitano; Mattia Bozzetti; Rosario Caruso; Monica Guberti; Ileana Frau; Bobbi Smuck; Gionata Fiorino; Franco Scaldaferri; Lucrezia Laterza; Antonio Gasbarrini; Vincenzina Mora展开收起
作者单位
1. Scientific Direction – Fondazione Policlinico Universitario IRCCS, Università Cattolica del Sacro Cuore Rome, Rome, Italy; 2. Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; 3. Direction of Health Professions, ASST Cremona, Cremona, Italy; 4. Department of Biomedical Sciences for Health, University of Milan, Milan, Italy; 5. Health Professions Research and Evidence Transfer Unit, IRCCS MultiMedica, Sesto San Giovanni, Italy; 6. Nursing and Allied Health Professions, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy; 7. Ass. Prime Site Director, Strategic Site Solutions EMEA - IQVIA, Milan, Italy; 8. Department of Ophthalmology, Ivey Eye Institute, St. Joseph’s Health Care, London, Canada; 9. Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, Rome, Italy; 10. Centro Malattie dell’Apparato Digerente (CEMAD), Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy展开收起
PDF源文件 DOI 网页
210 天

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

作者
Revathi Ananthakrishnan; Patrick Mitchell; Dong Xi; Gu Mi; Gina D’Angelo; Haijun Ma; Yujun Wu; Philip He展开收起
作者单位
1. Bristol-Myers Squibb (BMS), Princeton, USA; 2. AstraZeneca (AZ), Gaithersburg, USA; 3. Gilead, Foster City, USA; 4. Sanofi, Cambridge, USA; 5. Revolution Medicines, Redwood City, USA; 6. Oncolytics Biotech Inc, San Diego, USA; 7. Daiichi Sankyo, Inc, Basking Ridge, USA展开收起
PDF源文件 DOI 网页
182 天

The Effect of Covariate Adjustment for Cox Regression in Cardiovascular Outcome Trials

作者
Alexander Przybylski; Björn Holzhauer; Simon Wandel展开收起
作者单位
1. Novartis Pharmaceuticals UK Ltd., London, UK; 2. Novartis Pharma AG, Basel, Switzerland展开收起
PDF源文件 DOI 网页
303 天

Current Status and Construction Requirements of Drug Clinical Trial Institutions in Sichuan Province in China

作者
Shuxia Shi; Shangyuan Qin; Qin Yu展开收起
作者单位
1. National Drug Clinical Trial Institution of West China Second University Hospital, Sichuan University, Chengdu, China; 2. NMPA Key Laboratory for Technical Research on Drug Products In Vitro and In Vivo Correlation, Chengdu, China; 3. Children’s Medicine Key Laboratory of Sichuan Province, Chengdu, China; 4. Key Laboratory of Birth Defects and Related Diseases of Women and Children, Sichuan University, Ministry of Education, Chengdu, China; 5. Department of Pharmacy, Chengdu Fifth People’s Hospital, Chengdu, China展开收起
PDF源文件 DOI 网页
112 天

The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA

作者
Ling Tang; Songmei Xie; Lijia Yuan; Xiaowen Xu; Xing Ai; Tian Zhao; Zhimin Yang展开收起
作者单位
1. Center for Drug Evaluation, National Medical Products Administration, Beijing, The People’s Republic of China展开收起
PDF源文件 DOI 网页
286 天

Utilization of Clinical Evaluation Reports in Japan’s Medical Device Approvals: Insights from Review Data on Approved Devices

作者
Koji Yamada; Daisuke Obata; Jun Matsubayashi; Mayumi Yamanaka; Akiko Hinomura; Hiromu Kutsumi; Shin-ya Morita; Shu Kasama展开收起
作者单位
1. Center for Clinical Research and Advanced Medicine, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Japan; 2. Asahi Kasei Medical Co., Ltd., Tokyo, Japan; 3. Clinical & Translational Research Center, Kobe University Hospital, Kobe, Japan; 4. Medical Research Support Center, University of Fukui Hospital, Eiheiji-cho, Yoshida-gun, Fukui, Japan; 5. Department of Pharmacotherapeutics, Shiga University of Medical Science, Seta Tsukinowa-cho, Otsu, Japan展开收起
PDF源文件 DOI 网页

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。